Back
2018
Deal

TOLREMO closes Series A financing of CHF 9 million

TOLREMO therapeutics AG, a privately held Swiss biotech company and ETH Zurich Spin-Off, completed a series A financing round of CHF 9.0 million. The round was led by BioMedPartners with Redalpine and Altos Venture as well as TOLREMO’s existing shareholders. The capital increase will be used to advance two major drug development programs to prevent drug resistance in cancer therapies.

VISCHER advised TOLREMO; the VISCHER team includes Dr. Matthias Staehelin (Partner), Angelo Imperiale (Associate) and Luzius Zumstein (Associate), all Corporate.

 

 

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions